TFCP2

Across TCGA pan-cancer cohorts, TFCP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFCP2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TFCP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TFCP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where TFCP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.432	1.000	.026	13	view →
PDAC	OS	Tertile	All	0.534	0.285	.022	9	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.482	.040	1	view →
LUAD	DFS	Median	All	1.000	0.899	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFCP2–HNSC (OS)

Open the HNSC breakdown →